Core Insights - Karyopharm Therapeutics (KPTI) shares fell 18.3% following mixed results from a late-stage study of selinexor combined with Incyte's Jakafi for treating myelofibrosis [1][7] Study Results - The phase III SENTRY study involved 353 patients randomized to receive either selinexor plus Jakafi or placebo plus Jakafi [2] - The study met its first co-primary endpoint, showing a statistically significant 35% or more reduction in spleen volume (SVR35) in 50% of patients receiving the combination therapy, compared to 28% for Jakafi alone [3][5] - However, the second co-primary endpoint, absolute total symptom score (Abs-TSS), was not met, with similar symptom improvements observed in both treatment arms [3][6] Drug Background - Selinexor, marketed as Xpovio, is FDA-approved for multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma [4] - The drug is also available in the EU and UK under the name Nexpovio for multiple myeloma indications [4] Safety and Efficacy - The combination therapy demonstrated a manageable safety profile consistent with known effects of selinexor and Jakafi, with no new safety signals identified [11] - A promising overall survival trend was noted, with a hazard ratio of 0.43 suggesting potential survival advantages [9] Future Directions - Karyopharm plans to engage with the FDA to review the full SENTRY study dataset and discuss regulatory filing plans [15] - The company aims to present additional data from the SENTRY study at an upcoming medical conference [15] - Selinexor is also being evaluated in other oncology indications, and Karyopharm has another candidate, eltanexor, in mid-stage development for myelodysplastic neoplasms [16] Market Context - Karyopharm's stock has declined 20.8% over the past six months, compared to a 10.3% decline in the industry [6]

Fourth Quarter 2025 Financial Results & Business Update February 12, 2026 On Today's Call • Welcome Brendan Strong, SVP, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer and Head of Research • Commercial Highlights and Myelofibrosis Commercial Opportunity Sohanya Cheng, Chief Commercial Officer and Head of Business Development • Financial Results and Guidance Lori Macomber, Chief Financial Officer and Treasurer ...